Please login to the form below

Not currently logged in
Email:
Password:

Gilead

This page shows the latest Gilead news and features for those working in and with pharma, biotech and healthcare.

EMA begins accelerated review of Gilead’s Trodelvy for triple-negative breast cancer

EMA begins accelerated review of Gilead’s Trodelvy for triple-negative breast cancer

The European Medicines Agency (EMA) has begun an accelerated review of Gilead’s Trodelvy for the treatment of advanced triple-negative breast cancer. ... Gilead is also testing Trodelvy’s potential in non-small cell lung cancer and metastatic

Latest news

More from news
Approximately 187 fully matching, plus 390 partially matching documents found.

Latest Intelligence

  • Setting up for success in a post-Brexit, post-pandemic Britain Setting up for success in a post-Brexit, post-pandemic Britain

    and running, ahead of our UK marketing authorisation in IBD, through our partnership with Gilead. ... With a focus on inflammatory and fibrotic conditions, we have submitted a marketing application through our partnership with Gilead for a new treatment

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers Squibb’s acquisition of Juno Therapeutics, as well as the merger and acquisition agreements between Novartis/Spark and

  • The search for effective drug treatments for COVID-19 The search for effective drug treatments for COVID-19

    The European Commission has signed a joint procurement agreement for Gilead’s COVID-19 antiviral treatment remdesivir. ... Since January, Gilead has taken multiple steps to ramp up production and rapidly build supply in recognition of the lengthy

  • Switzerland: a life sciences hub Switzerland: a life sciences hub

    The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Lundbeck, MSD (Merck Sharp &Dohme), Pfizer, Sanofi and Takeda among others.

  • Working together against COVID-19 Working together against COVID-19

    There were questions asked directly to Gilead, and also peers, about Compassionate Use and Extended Access. ... Subsequently, Gilead dropped remdesivir’s orphan drug designation based on its potential as a coronavirus treatment.

More from intelligence
Approximately 5 fully matching, plus 53 partially matching documents found.

Latest appointments

More from appointments
Approximately 6 fully matching, plus 20 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 15 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mednet Group

Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics